patient recruitment success

✔️ Protocol deviation risk

✔️ Startup speed and regulatory approval timelines

✔️ Data quality and eCRF completion compliance

Some tools also integrate natural language processing (NLP) to scan free-text site responses, investigator CVs, or prior inspection reports to uncover potential red flags.

Example vendors and tools include:

• TrialHub: Combines historical site performance with real-world epidemiological data
• SiteIQ (IQVIA): Uses predictive modeling based on global site benchmarking
• Antidote Match: Uses AI to match patients to studies and model site potential

Data Sources Used in AI Feasibility Models

AI-based feasibility platforms aggregate data from numerous sources to fuel their predictive engines:

Data Source	Type of Input	Usage in Feasibility
CTMS	Enrollment history, protocol deviations, timelines	Scores past site performance
EDC Systems	eCRF completion, data query response times	Predicts data quality compliance
EHR Integration	Patient population, ICD-10 codes	Estimates actual recruitment potential
Trial Registries	Study metadata, sponsor affiliations	Cross-validates investigator experience

For example, a site may self-report a capacity to recruit 60 patients for a metabolic trial. An AI tool might access EHR data, recognize only 20 qualified patients in the database, and flag this discrepancy for manual review—improving selection accuracy.

Publicly available registries such as Canada’s Clinical Trials Database can also be integrated for validation purposes.

Core Functionalities of AI-Based Site Selection Platforms

AI feasibility tools typically include several key modules:

• Predictive Enrollment Modeling: Analyzes patient population and prior enrollment speed
• Feasibility Scoring Engines: Generates composite scores based on predefined KPIs
• Automated Questionnaire Review: Uses NLP to detect inconsistencies or gaps
• Risk Ranking: Categorizes sites by low/medium/high risk for deviations or noncompliance
• Dynamic Dashboards: Visualize site performance, regulatory readiness, and projected ROI

These platforms often integrate into CTMS and eTMF systems, allowing sponsors to move directly from feasibility to activation workflows.

Benefits of Using AI in Feasibility Planning

Adopting AI-based feasibility solutions brings measurable improvements:

• ✔️ Reduced site activation time by 20–40%
• ✔️ Lower protocol deviation rates
• ✔️ Better enrollment forecasting accuracy
• ✔️ Centralized, audit-ready documentation of decisions
• ✔️ Objective and reproducible site selection process

In addition, AI tools reduce the reliance on subjective site self-assessments, which have historically led to overestimated recruitment capabilities and inconsistent site performance.

Regulatory Considerations and Compliance

While AI tools provide operational advantages, they must align with regulatory expectations for site selection documentation. Regulatory guidelines from the FDA, EMA, and ICH GCP specify:

• ✔️ Sponsors must document how and why a site was selected
• ✔️ Tools used must be validated and audit-ready
• ✔️ Site scoring models should be reproducible and transparent
• ✔️ Electronic records must comply with 21 CFR Part 11 and Annex 11

Sponsors using AI should retain documentation of algorithm logic, input data sources, risk scores, and any manual overrides. These materials must be made available during audits and inspections.

Challenges and Limitations

Despite the advantages, several challenges must be addressed:

• ❌ Data privacy concerns, especially in EHR integrations (GDPR compliance)
• ❌ Bias in historical data used to train AI models
• ❌ Limited AI adoption in certain regulatory environments
• ❌ Cost of implementation and platform validation
• ❌ Need for human oversight to interpret AI-generated outputs

These can be mitigated through hybrid models combining AI recommendations with expert review, robust SOPs for AI-assisted feasibility, and use of explainable AI models with transparent logic.

Case Study: Oncology Trial Using AI Feasibility Scoring

In a recent global Phase III oncology trial, the sponsor deployed an AI feasibility platform across 120 potential sites. Key outcomes:

• ➤ 32% reduction in average site startup time
• ➤ 18% increase in patient enrollment rates
• ➤ 25% fewer protocol deviations from selected sites
• ➤ All site selection decisions were documented and passed regulatory audit

The platform integrated CTMS and external registry data, flagged 14 sites as high-risk, and prioritized 60 low-risk, high-potential sites. This enabled resource optimization and stronger trial performance metrics.

Best Practices for Implementing AI-Based Feasibility Tools

• ✔️ Start with a pilot study to validate tool accuracy and user acceptance
• ✔️ Document all model assumptions, logic, and scoring weights
• ✔️ Train feasibility and QA teams in interpreting AI outputs
• ✔️ Ensure data security, consent, and privacy compliance
• ✔️ Create audit trail reports for all AI-generated recommendations

Conclusion

AI is rapidly changing the way feasibility assessments and site selection are conducted in clinical research. By analyzing historical and real-time data, AI tools can predict site performance with higher accuracy, reduce risk, and improve compliance. Sponsors and CROs that embrace AI-powered feasibility tools position themselves to execute faster, more cost-effective, and regulatorily sound trials. As these tools evolve, they will become integral to the digital transformation of global clinical trial operations.